Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Strong Abraxane Cancer Data Promised, But Abraxis Mum On Spin-Off Details

This article was originally published in The Pink Sheet Daily

Executive Summary

Veteran Merck scientist recruited for personalized-medicine push.
Advertisement

Related Content

Enzon Hunkers Down, Canceling Spin-Out To Guard Cash
Newly Independent Myriad Diagnostics Will Pursue Product Acquisitions
Newly Independent Myriad Diagnostics Will Pursue Product Acquisitions
Abraxis Splits Injectable Generics Business Into Separate Unit
FDA Approves APP's Abraxane Paclitaxel Formulation

Topics

Advertisement
UsernamePublicRestriction

Register

PS068500

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel